Nuclear Imaging Agent Measures, Monitoring Cathepsin B Activity

 

November 13, 2009

A new imaging agent, Cat B 750 FAST, for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo was released at the 2009 American Heart Association meeting.

VisEn Medical Inc. said cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis. The new agent is expected to have a significant impact in cardiovascular disease research.

Cathepsin B proteases play an important role in disease progression and host response in several disease areas, and are key biomarkers in assessing and characterizing disease states. The new Cat B 750 FAST agent is designed to complement in vitro and in vivo protease readouts from cell-based assays and VisEn’s existing in vivo agent product lines, providing earlier imaging time points and narrower specificity profiles of cathepsin B within the cathepsin family of proteases.

The new Cat B 750 FAST agent represents an additional protease-sensing agent developed from VisEn’s new FAST (Fluorescent Activatable Sensor Technology) in vivo agent platform. FAST agents are based on high-performance activatable smaller molecules that combine advanced biomarker specificity with optimized biocompatibility and rapid pharmacokinetics. These benefits allow for precise measurement and monitoring of key disease biomarkers in vivo.

For more information: www.visenmedical.com